文献速递心力衰竭与心肌病

Jmjd4促进心肌细胞Pkm2降解并保护扩张型心肌病

Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy.
PubMed 文献 · Circulation · 2023-04-17

该研究探讨Jmjd4在扩张型心肌病(DCM)中的作用及机制。发现DCM患者心脏中Jmjd4表达显著降低,心肌细胞特异性敲除Jmjd4导致自发性DCM和线粒体呼吸严重受损,机制上Jmjd4通过Hsp70介导的分子伴侣自噬促进Pkm2降解,且Pkm2激动剂TEPP-46对Jmjd4缺失诱导的DCM及压力负荷诱导的心力衰竭有显著治疗作用。

要点

  • DCM患者心脏中Jmjd4表达显著降低。
  • 心肌细胞Jmjd4缺失导致自发性DCM和线粒体呼吸严重受损。
  • Jmjd4通过Hsp70介导的分子伴侣自噬促进Pkm2降解,依赖Pkm2 K66羟基化。

核心结论

  • Jmjd4通过降解Pkm2维持成年心肌细胞代谢稳态,其缺失导致DCM。
  • Jmjd4和Pkm2可能成为治疗DCM及其他代谢功能障碍性心脏病的靶点。

研究设计与样本

  • 检测DCM患者心脏中Jmjd4表达。
  • 在体内条件性敲除和过表达心肌细胞Jmjd4以研究其在DCM中的作用。
  • 采用RNA测序、代谢物谱分析和质谱解析Jmjd4调控心脏代谢和肥厚的分子机制。

主要发现

  • DCM患者心脏中Jmjd4表达显著降低。
  • 诱导性心肌细胞特异性敲除Jmjd4导致自发性DCM伴线粒体呼吸严重受损。
  • Jmjd4缺失心脏中Pkm2大幅积累,Pkm2在健康成年心肌细胞中通常缺失但在心肌病中升高。
  • Jmjd4与Hsp70相互作用,通过分子伴侣自噬介导Pkm2降解,依赖Jmjd4对Pkm2 K66的羟基化。
  • Pkm2激动剂TEPP-46对Jmjd4缺失诱导的DCM及压力负荷诱导的心力衰竭有显著治疗作用。

关键数值与推荐

  • DCM患者心脏中Jmjd4表达显著降低。
  • 心肌细胞特异性敲除Jmjd4导致自发性DCM和线粒体呼吸严重受损。
  • Jmjd4通过Hsp70介导的分子伴侣自噬促进Pkm2降解,依赖Pkm2 K66羟基化。
  • Pkm2激动剂TEPP-46对Jmjd4缺失诱导的DCM和压力负荷诱导的心力衰竭有显著治疗作用。

临床怎么用

  • Jmjd4表达降低可能与DCM发病相关,可作为潜在生物标志物。
  • 增强Pkm2酶活性(如TEPP-46)可能治疗DCM及代谢功能障碍相关心脏病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A large portion of idiopathic and familial dilated cardiomyopathy (DCM) cases have no obvious causal genetic variant. Although altered response to metabolic stress has been implicated, the molecular mechanisms underlying the pathogenesis of DCM remain elusive. The JMJD family proteins, initially identified as histone deacetylases, have been shown to be involved in many cardiovascular diseases. Despite their increasingly diverse functions, whether JMJD family members play a role in DCM remains unclear. METHODS: We examined Jmjd4 expression in patients with DCM, and conditionally deleted and overexpressed Jmjd4 in cardiomyocytes in vivo to investigate its role in DCM. RNA sequencing, metabolites profiling, and mass spectrometry were used to dissect the molecular mechanism of Jmjd4-regulating cardiac metabolism and hypertrophy. RESULTS: We found that expression of Jmjd4 is significantly decreased in hearts of patients with DCM. Induced cardiomyocyte-specific deletion of Jmjd4 led to spontaneous DCM with severely impaired mitochondrial respiration. Pkm2, the less active pyruvate kinase compared with Pkm1, which is normally absent in healthy adult cardiomyocytes but elevated in cardiomyopathy, was found to be drastically accumulated in hearts with Jmjd4 deleted. Jmjd4 was found mechanistically to interact with Hsp70 to mediate degradation of Pkm2 through chaperone-mediated autophagy, which is dependent on hydroxylation of K66 of Pkm2 by Jmjd4. By enhancing the enzymatic activity of the abundant but less active Pkm2, TEPP-46, a Pkm2 agonist, showed a significant therapeutic effect on DCM induced by Jmjd4 deficiency, and heart failure induced by pressure overload, as well. CONCLUSIONS: Our results identified a novel role of Jmjd4 in maintaining metabolic homeostasis in adult cardiomyocytes by degrading Pkm2 and suggest that Jmjd4 and Pkm2 may be therapeutically targeted to treat DCM, and other cardiac diseases with metabolic dysfunction, as well.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Tang Y, Feng M, Su Y, et al. Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy. Circulation. 2023. PMID: 37066795. doi:10.1161/CIRCULATIONAHA.123.064121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。